Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

Caicun Zhou; You Lu; Sang‐We Kim; Thanyanan Reungwetwattana; Jianying Zhou; Yiping Zhang; Jianxing He; Jin‐Ji Yang; Ying Cheng; Se‐Hoon Lee; Jianhua Chang; Jian Fang; Zhe Liu; Lilian Bu; Qian Li; Tingting Xu; V.R. Archer; Magalie Hilton; Mingzhu Zhou; Li Zhang

doi:10.1016/j.jtocrr.2024.100700

Abstract

With four additional years of follow-up, these updated results confirm the clinical benefit and manageable safety of alectinib in Asian patients with advanced ALK-positive NSCLC, and confirm alectinib as a standard-of-care treatment for patients with advanced ALK-positive NSCLC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/69dee0d15e217d93a5558d9b https://doi.org/10.1016/j.jtocrr.2024.100700

View Full Paper

Ask AI

Bookmark

Share

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

Abstract

Discussion

Cite This Study

Alectinib Versus Crizotinib in Asian Patients With Treatment-Naïve Advanced ALK-Positive NSCLC: Five-Year Update From the Phase 3 ALESIA Study

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from JTO Clinical and Research Reports

Keep reading

More related papers

More from JTO Clinical and Research Reports